NASDAQ · TNDM
Healthcare · Medical - Devices
$17.43
Up+$0.28 (+1.63%)
Updated Oct 25, 2026, 12:41 AM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · TNDM
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 23, 2026
TNDM closed at $17.43 after 20 trading sessions, up 6.15% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 23, 2026 | $17.06 | $17.56 | $16.89 | $17.43 | 1.82M |
| Oct 22, 2026 | $16.47 | $17.20 | $16.24 | $17.15 | 1.87M |
| Oct 21, 2026 | $16.60 | $16.95 | $16.12 | $16.35 | 1.53M |
| Oct 20, 2026 | $16.47 | $16.865 | $16.37 | $16.52 | 1.59M |
| Oct 19, 2026 | $16.23 | $16.5246 | $16.00 | $16.38 | 1.27M |
| Oct 16, 2026 | $16.61 | $17.25 | $16.14 | $16.24 | 1.63M |
| Oct 15, 2026 | $16.01 | $16.545 | $15.61 | $16.52 | 4.59M |
| Oct 14, 2026 | $16.64 | $16.70 | $15.86 | $16.01 | 2.22M |
| Oct 13, 2026 | $16.235 | $16.80 | $15.715 | $16.65 | 1.71M |
| Oct 12, 2026 | $16.11 | $16.9099 | $15.86 | $16.45 | 1.58M |
| Oct 9, 2026 | $15.64 | $16.13 | $15.38 | $16.11 | 1.43M |
| Oct 8, 2026 | $15.57 | $15.765 | $15.125 | $15.675 | 2.9M |
| Oct 7, 2026 | $15.80 | $16.64 | $15.73 | $15.84 | 2.27M |
| Oct 6, 2026 | $16.77 | $17.05 | $15.94 | $16.16 | 1.48M |
| Oct 5, 2026 | $16.50 | $16.95 | $16.14 | $16.52 | 1.79M |
| Oct 2, 2026 | $16.66 | $17.35 | $16.27 | $16.50 | 2.19M |
| Oct 1, 2026 | $16.42 | $16.58 | $16.04 | $16.50 | 2.4M |
| Sep 30, 2026 | $16.63 | $16.68 | $16.00 | $16.31 | 2.2M |
| Sep 29, 2026 | $16.24 | $16.645 | $15.87 | $16.57 | 1.89M |
| Sep 28, 2026 | $15.60 | $16.535 | $15.52 | $16.42 | 2.85M |
The latest Smart Investors Daily articles mentioning TNDM.
Company
Market Activity
Research & News
TNDM research
Company profile and research snapshot.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Equal-Weight | — |
| Sep 30, 2026 | Citigroup | Neutral | — |
| Sep 24, 2026 | Truist Securities | Buy | — |
| Aug 21, 2026 | William Blair | Outperform | — |
| Aug 7, 2026 | RBC Capital | Outperform | — |
No generated briefing is available yet.
Benzinga · Oct 12, 2026
Tandem Diabetes Care (NASDAQ:TNDM) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time
Benzinga · Oct 7, 2026
Barclays analyst Christopher Pasquale initiates coverage on Tandem Diabetes Care (NASDAQ:TNDM) with a Equal-Weight rating and announces Price Target of $18.
Yahoo · Oct 1, 2026
SAN DIEGO, October 01, 2026--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2026 results after the financial markets close on Thursday, November 5, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2026 financial and operating results.
Yahoo · Oct 1, 2026
Tandem Diabetes Care has recently launched its Tandem Mobi automated insulin delivery system in 12 countries across Europe and Israel, using Dexcom G7 continuous glucose monitoring and Control-IQ+ technology to automatically adjust insulin every 5 minutes. The international rollout of this small, iPhone-controlled pump with flexible wear options and a 200-unit cartridge broadens Tandem’s technology ecosystem for people living with diabetes outside the United States. We’ll now explore how...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TNDM.
